Celcuity Inc.

13 days ago · seekingalpha.com

Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

21 days ago · globenewswire.com

MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

27 days ago · globenewswire.com

MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy.

28 days ago · defenseworld.net

Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 6,621 shares of the company's stock, valued at approximately $693,000. Several other hedge funds have also

1 month ago · seekingalpha.com

Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with SG&A surging for launch, but a strengthened $754M cash position provides funding visibility into 2029. VIKTORIA-1 data show REVTORPYK delivers a step-change in efficacy and tolerability, supporting rapid physician adoption and a potential blockbuster franchise.

1 month ago · benzinga.com

Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.

1 month ago · seekingalpha.com

Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript

1 month ago · marketbeat.com

Celcuity NASDAQ: CELC said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026 following its recent FDA approval.

1 month ago · globenewswire.com

MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced financial results for the second quarter ended June 30, 2026 and other recent business developments.

1 month ago · defenseworld.net

California State Teachers Retirement System lifted its holdings in Celcuity, Inc. (NASDAQ: CELC) by 91.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,580 shares of the company's stock after buying an additional 12,201 shares during the quarter. California State Teachers Retirement